Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2009 Results
Date:2/16/2010

ROCKVILLE, Md., Feb. 16 /PRNewswire-FirstCall/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA), a biopharmaceutical company focused on the development and commercialization of clinical-stage products for central nervous system disorders, today announced financial and operational results for the fourth quarter and full year ended December 31, 2009.  

Vanda reported a net loss of $9.2 million for the fourth quarter of 2009, compared to $7.7 million for the third quarter of 2009 and $7.5 million for the fourth quarter of 2008.  Total revenue for the fourth quarter of 2009 was $4.5 million, consisting of $2.6 million in upfront licensing revenue and $1.9 million in product revenue for inventory sold to Novartis Pharma AG (Novartis).  The remaining $197.4 million in deferred revenue relating to the $200.0 million upfront payment received from Novartis pursuant to the Fanapt™ (iloperidone) license agreement will be recognized ratably ($2.2 million per month) through May 2017.  Total expenses for the fourth quarter of 2009 were $13.8 million, compared to $7.7 million for the third quarter of 2009 and $7.7 million for the fourth quarter of 2008.  Research and development (R&D) expenses for the fourth quarter of 2009 were $2.3 million, compared to $2.1 million'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Vanda Pharmaceuticals Reports Second Quarter 2009 Results
2. Vanda Pharmaceuticals to Announce Second Quarter 2009 Financial Results on August 10, 2009
3. Vanda Pharmaceuticals to Present Data on Fanapt(TM) and Tasimelteon at the 162nd American Psychiatric Association Annual Meeting
4. Vanda Pharmaceuticals Reports First Quarter 2009 Results
5. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results
6. Vanda Pharmaceuticals Reports Third Quarter 2008 Results
7. Vanda Pharmaceuticals Declares Dividend Distribution of Preferred Stock Purchase Rights
8. Vanda Pharmaceuticals to Announce Second Quarter 2008 Financial Results on August 5, 2008
9. LabCorp(R) and Vanda Pharmaceuticals Collaborate to Offer Genetic Tests
10. Vanda Pharmaceuticals to Present at the Bank of America 2008 Healthcare Conference
11. Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/21/2013)... , May 21, 2013 ... Market Research ( http://www.transparencymarketresearch.com ) "Biochip Products and Services ... Tests) - U.S. Industry Analysis, Size, Share, Growth, Trends and Forecast, ... in 2011 and is expected to grow at a ... an estimated value of USD 4.7 billion in 2018. ...
(Date:5/21/2013)... 21, 2013 As the R&D ... push within the industry to deliver better products, ... and pharma companies often means turning big ideas ... developed in collaboration with Sensidose AB and Recipharm, ... bring products to market sooner. The partnership resulted ...
(Date:5/21/2013)... 2013 Many have long discussed the ... acne. Recently physicians from Clinical Psychiatry.com readdressed ... the skin, and suggested using hypnotherapy and ... produced from stress that cause acne. , Doctors in ... acne brings about, stress causes changes in the skin ...
(Date:5/21/2013)... Norristown, PA (PRWEB) May 21, 2013 ... company, today announced that Dr. Charles Signorino, the Company’s ... on April 1, 2013 after 32 years of service. ... Adolfo Gomez, Emerson’s current President, has been named as ... recognized luminary in the pharmaceutical industry, having made a ...
Breaking Biology Technology:The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 2The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 3The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 4The U.S. Biochip Products and Services Market is Expected to Reach USD 4.7 Billion in 2018: Transparency Market Research 5The Development of an Innovative Microtablet Dosage Form, a Success Story: Live Webinar Hosted by Xtalks 2Adult Acne Treatment, Probiotic Action Explains How Hypnotherapy and Probiotics May Cure Various Skin Conditions 2Emerson Resources Announces CEO Retirement and Appointment of Successor 2Emerson Resources Announces CEO Retirement and Appointment of Successor 3
... The American Filtration ... in San Antonio, Texas, USA. AFS is holding its 23rd Annual Conference, March 22-25, 2010 ... held on March 22nd. Five of these courses are on the topics of air filtration, ... ...
... , , , , , , , , ... China-Biotics, Inc.,(Nasdaq: CHBT ) ("China-Biotics", "the Company"), a leading Chinese ... today announced its financial results for,the third quarter of its 2010 ... Third Quarter 2010 Highlights, -- Net ...
... , , JERUSALEM, Israel , ... a developer,of alternative drug delivery systems, announced today that its Chief,Scientific ... the Third,International Conference on Advanced Technologies and Treatments for Diabetes,(ATTD) to ... 2010 . Dr. Kidron,will present the following abstract in Hall B ...
Cached Biology Technology:Air Filtration and Gas/Solid Separation Training by the American Filtration and Separations Society 2Air Filtration and Gas/Solid Separation Training by the American Filtration and Separations Society 3Air Filtration and Gas/Solid Separation Training by the American Filtration and Separations Society 4China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 2China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 3China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 4China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 5China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 6China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 7China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 8China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 9China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 10China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 11China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 12China-Biotics, Inc. Reports Third Quarter Fiscal 2010 Financial Results 13Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland 2Oramed's Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the Third International Conference on Advanced Technologies and Treatments for Diabetes in Basel, Switzerland 3
(Date:5/21/2013)... -- Royal Philips Electronics (NYSE: PHG, AEX: PHIA) today ... with Philips, industry leading Live 3D TEE, now offers ... available Live 3D TEE and ICE will be shown ... official meeting for the European Association of Percutaneous Cardiovascular ... in 2012, Philips CX50 xMATRIX has been the only ...
(Date:5/21/2013)... epigenetic modifications, which alter the way genes function ... be detected in the blood of pregnant women ... to foretell depression in the weeks after giving ... become debilitating. , The findings of the small ... in the journal Molecular Psychiatry . , ...
(Date:5/20/2013)... antibiotic colistin are also commonly resistant to antimicrobial ... a study in mBio , the online ... Cross-resistance to colistin and host antimicrobials LL-37 and ... attack, could mean that patients with life-threatening multi-drug ... immune response. Colistin is a last-line drug for ...
Breaking Biology News(10 mins):Philips CX50 xMATRIX now offers world-class interventional and diagnostic features on single portable system 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 2Genetic predictors of postpartum depression uncovered by Hopkins researchers 3Resistance to last-line antibiotic makes bacteria resistant to immune system 2Resistance to last-line antibiotic makes bacteria resistant to immune system 3
... Tampa, FL (Sept. 21, 2010) -- The University of ... and the State of Florida Oil Spill Academic Task ... February 9-11, 2011, at the Hilton St. Petersburg Bayfront ... are invited on substantial and original research on all ...
... -- A new weight loss study conducted by Ben-Gurion University ... or milk products lost more weight on average than those who ... diet, researchers also found participants with the highest dairy calcium intake, ... mg of dairy calcium), lost about 12 pounds (6 kg.) at ...
... crops requires efficient, economical harvesting systems that do not ... of the world,s citrus is now harvested manually, but ... is expected to increase in the next few years, ... Brazil. The citrus industry is ramping up efforts to ...
Cached Biology News:Florida institutions to host Gulf of Mexico oil spill conference 2Drink milk and lose more weight, according to Ben-Gurion University of the Negev research 2Winter drought stress can delay flowering, prevent fruit loss in orange crops 2
...
... MBS Start up kit. Includes configured Laptop ... of 1 MultiBlock satellite thermal Cycler ... User friendly software. Store/track run ... heated lid. Outstanding uniformity. Advanced ...
For relative and/or absolute quantification with standard accuracy requirements using MS or NMR instruments...
For testing the AQUA technique on your MS instruments....
Biology Products: